Galectin Therapeutics
GALT • NASDAQ
Galectin Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jack W. Callicutt, with a market cap of $182.5M.
CEOJack W. Callicutt
Market Cap$182.5M
Biotechnology
Healthcare
Employees14.0
Websitegalectintherapeutics.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Galectin Therapeutics
Date
Monday, March 30, 2026 (in 2 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$0.10
Earnings History
Past 12 earnings reports for Galectin Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 2025 | Q3 2025 | -$0.13Est: -$0.11 | -18.2% | - | — |  10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.12Est: -$0.16 | +25.0% | - | — | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.15 | — | - | — | 10-Q |
| Mar 31, 2025 | Q4 2024 | -$0.19Est: -$0.21 | +9.5% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.18Est: -$0.20 | +10.0% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.20Est: -$0.16 | -25.0% | - | — | 10-Q |
| May 15, 2024 | Q1 2024 | -$0.19Est: -$0.16 | -18.8% | - | — | 10-Q |
| Mar 29, 2024 | Q4 2023 | -$0.16Est: -$0.16 | 0.0% | - | — | 10-K |
| Nov 13, 2023 | Q3 2023 | -$0.24Est: -$0.16 | -50.0% | - | — | — |
| Aug 14, 2023 | Q2 2023 | -$0.15Est: -$0.21 | +28.6% | - | — | 10-Q |
| May 15, 2023 | Q1 2023 | -$0.19Est: -$0.21 | +9.5% | - | — | 10-Q |
| Mar 30, 2023 | Q4 2022 | -$0.18Est: -$0.17 | -5.9% | - | — | — |